TUSTIN, Calif., May 13, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP), a biopharmaceutical company focused on advancing bavituximab, a novel immuno-oncology agent in Phase III development, today announced the presentation of three posters at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29-June 2, 2015 in Chicago, Illinois.

Abstract: 3059
Title: Phosphatidylserine targeting antibody in combination with anti-PD-1 antibody treatment activates infiltrating T lymphocytes of the spleen and tumor microenvironment in pre-clinical models of melanoma and breast cancer
Presenter: Xianming Huang, Ph.D., The University of Texas Southwestern Medical Center
Session: Developmental Therapeutics—Immunotherapy
Track(s): Developmental Therapeutics and Translational Research
Session Type: General Poster Session
Time and Location: Saturday, May 30 8:00 AM - 11:30 AM CDT, S Hall A

Abstract: 3060
Title: Activation of CD8+ tumor infiltrating lymphocytes by bavituximab in a 3D ex vivo system of lung cancer patients
Presenter: Soner Altiok, M.D, Ph.D., H. Lee Moffitt Cancer Center & Research Institute
Session: Developmental Therapeutics—Immunotherapy
Track(s): Developmental Therapeutics and Translational Research
Session Type: General Poster Session
Time and Location: Saturday, May 30  8:00 AM - 11:30 AM CDT, S Hall A

Abstract: 4109
Title: A phase I/II study of bavituximab and sorafenib in advanced hepatocellular carcinoma (HCC)
Presenter: Adam Charles Yopp, M.D., The University of Texas Southwestern Medical Center
Session: Gastrointestinal (Noncolorectal) Cancer
Track(s): Gastrointestinal (Noncolorectal) Cancer
Session Type: General Poster Session
Time and Location: Monday, Jun 1 8:00 AM - 11:30 AM CDT, S Hall A

In addition, Peregrine will be hosting ASCO conference attendees at booth #22107.

About Peregrine Pharmaceuticals, Inc.

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials for the treatment and diagnosis of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also advancing a molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of multiple solid tumor types. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. For more information, please visit www.peregrineinc.com.

CONTACT: Christopher Keenan

         Peregrine Pharmaceuticals, Inc.

         (800) 987-8256

         info@peregrineinc.com

News Provided by Acquire Media